从复杂HIV方案转换为单片比克替拉韦-来那帕韦的3期试验
ARTISTRY-1是一项在15国开展的随机、开放标签、活性对照、非劣效3期试验,纳入病毒学抑制的HIV-1感染者,比较转换为每日一次口服比克替拉韦-来那帕韦75mg/50mg单片方案与继续复杂方案。
要点
- 复杂方案经治且病毒学抑制者转换为单片方案非劣效于继续复杂方案。
- 第48周病毒载量≥50拷贝/mL比例两组均为1%,无耐药出现。
- 不良事件发生率相似,转换后治疗满意度提高。
核心结论
- 比克替拉韦-来那帕韦单片方案对复杂方案显示非劣效疗效,安全性相似且治疗满意度提高。
研究设计与样本
- ARTISTRY-1为随机、开放标签、活性对照、非劣效3期试验,在15国医院和诊所开展。
- 纳入复杂方案下病毒学抑制的HIV-1感染者,按2:1随机分配至转换单片方案组或继续复杂方案组。
- 共筛查729人,557人随机并治疗(单片方案组n=371,复杂方案组n=186)。
- 主要终点为第48周HIV-1 RNA≥50拷贝/mL的参与者比例,采用FDA Snapshot算法。
主要发现
- 第48周病毒载量≥50拷贝/mL者单片方案组3例(1%),复杂方案组2例(1%)。
- 未出现耐药;两组不良事件发生率相似。
- 因不良事件停药者单片方案组6例(2%),复杂方案组1例(1%)。
- 单片方案组发生5例死亡,均判定与研究药物无关。
关键数值与推荐
- 非劣效界值为4%。
- 主要终点病毒载量阈值为50拷贝/mL。
- 随机分组比例为2:1,按地理区域分层。
临床怎么用
- 对于因耐药、禁忌或药物相互作用无法使用单片方案而依赖复杂多片方案的HIV-1感染者,可考虑转换为比克替拉韦-来那帕韦单片方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-tablet regimens (STRs) revolutionised HIV-1 treatment, improving adherence and clinical outcomes; however, many people cannot take these due to resistance, contraindications, or drug-drug interactions, instead relying on complex multi-tablet regimens. Novel STRs are therefore needed. We aimed to evaluate the efficacy and safety of a novel STR, bictegravir-lenacapavir, in people with HIV-1. METHODS: ARTISTRY-1 was a randomised, open-label, active-controlled, non-inferiority phase 3 trial conducted at hospitals and clinics across 15 countries that enrolled people with HIV-1 with virological suppression on complex regimens. Participants were randomly assigned (using interactive technology, 2:1, stratified by geographical region) to switch to once-daily oral bictegravir-lenacapavir 75 mg/50 mg STR or continued complex regimen. The primary outcome was the proportion of participants with an HIV-1 RNA viral load of 50 copies per mL or higher at week 48 (US Food and Drug Administration Snapshot algorithm), assessed in all randomly assigned participants who received any dose of assigned treatment. This trial (active; enrolment complete) was registered with ClinicalTrials.gov (NCT05502341). FINDINGS: Between Jan 29 and Sept 26, 2024, 729 participants were screened; 557 were randomly assigned and treated (bictegravir-lenacapavir n=371; complex regimen n=186). At baseline, median age was 60 years (range 22-84), HIV treatment duration was 28 years (IQR 22-32); participants were taking a median of three antiretroviral pills per day (range 2-11). At week 48, an HIV-1 RNA viral load of 50 copies per mL or higher was observed in three (1%) participants receiving bictegravir-lenacapavir and two (1%) receiving a complex regimen (difference -0·3%; 95·002% CI -2·3 to 1·8), meeting the non-inferiority margin of 4%. No resistance emerged. Adverse event rates were similar between groups. Six (2%) participants discontinued bictegravir-lenacapavir and one (1%) discontinued their complex regimen due to adverse events. There were five deaths in the bictegravir-lenacapavir group, none of which were deemed related to study drug. Participants reported increased treatment satisfaction after switching to bictegravir-lenacapavir. INTERPRETATION: Bictegravir-lenacapavir STR demonstrated non-inferior efficacy to complex regimens, with a similar safety profile and increased treatment satisfaction. Bictegravir-lenacapavir offers new opportunities for HIV-1 treatment optimisation for people taking complex regimens. FUNDING: Gilead Sciences.
引用
- Orkin C, Ruane PJ, Hedgcock M, et al. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. Lancet. 2026. PMID: 41763229. doi:10.1016/S0140-6736(26)00307-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。